Digital health companies remain attractive investments, but the industry still faces regulatory uncertainty and increased enforcement. Understanding this regulatory landscape is crucial for predicting M&A market trends and making informed decisions about the value of a given company (and its data). In a new article for Mergers & Acquisitions magazine, Akerman Digital Health Team Leader Jordan Cohen provides an overview and insights on four major regulatory developments investors need to follow.